A live archive of receipt-bound excerpts from company earnings calls. No generated thesis, no recommendation — just the recorded language, its source coordinates, and a direct path into the ticker dossier or live Terminal.来自公司财报电话会的可追溯摘录档案。没有生成式投资结论，也没有推荐——只有原始表述、来源坐标，以及进入个股档案或实时终端的直接入口。
Start free in Terminal免费开始使用终端50 verified call records份已核验电话会记录 · 600 exact facts条精确事实 · 2026-09-07 → 2026-09-13
Browse the full archive page by page. Search on this page by ticker, period, category, or speaker; every card preview is a verbatim call excerpt.分页浏览完整档案。在本页按代码、期间、分类或发言人搜索；每张卡片预览均为电话会原文摘录。
Showing records 4129–4224 of 5581.显示第 4129–4224 条，共 5581 条。
“PEM delivered net sales of $1.7 billion and EBITDA of $36 million on 3% sequential volume growth, excluding the impact to volumes from our 2025 plant shutdowns.”
“To meet growing demand for the technical and maintenance expertise of our engine shops, which contributed revenue of $10 million in the first quarter, exclusive of intercompany sales, and to enhance our vertical integration, we continue to invest in deepening our in-house technical capabilities.”
“We are also raising our 2026 free cash flow margin outlook by 100 basis points to approximately 20%.”
“We're on track to deliver results in line with our 2026 earnings guidance of $5.51 to $5.61 a share.”
“Given our strong first quarter results, updated FX assumptions, and the prudence embedded in our second half outlook, we are raising our full year adjusted EPS guidance by $0.10 to $14.40 per share to $14.60 per share, reflecting growth of 10%-11%.”
“Free cash flow for the quarter was $12 million after $18.7 million of development capital expenditures net of divestitures.”
“We continue to target approximately 25% organic revenue growth, gross margins in the range of 30%-35% and mid-teens adjusted EBITDA margins excluding Starlab, with low teens free cash flow margins excluding Starlab as the platform continues to scale.”
“Importantly, this increased production outlook represents over 5% organic growth relative to our pro forma 2025 exit rate.”
“As previously indicated, we expect there to be significant earnings growth in 2027 as the positive impact from PENN 1 and PENN 2 lease-up takes effect, as well as the positive impact of the recent acquisition of Park Avenue Plaza.”
“Regionally, performance was strong in the Americas, where adjusted growth was 6% year-over-year, supported by higher volumes on key programs and new business wins.”
“Turning to our 2026 outlook, we are raising full-year total revenue guidance to $582 million-$592 million, representing 13%-14% year-over-year growth compared to our prior range of $570 million-$582 million.”
“The increase in gas-adjusted gross margin was driven by higher rates in customer growth of $10.3 million and the favorable effects of colder winter weather in 2026 of $0.9 million.”
“We continue to maintain our full-year adjusted EBITDA range of $778 million-$100 million, distributable cash flow range of $480 million-$510 million, maintenance capital range of $60 million-$70 million, and expansion capital range of $230 million-$250 million.”
“Maybe just as a follow-up, sort of applying maybe the same rubric to kind of the medium term, you know, the three-year guidance, I mean, 35% revenue CAGR is obviously significant, and margins going from 21% to 25% is material as well.”
“Adjusted EBITDA for Risk and Compliance Software was $19 million in the quarter, up 26.7% year-over-year, with adjusted EBITDA margin expanding 460 basis points to 29.2%.”
“Turning to the second quarter, our guidance reflects RASM growth of greater than 20% and stage-adjusted RASM up high teens year-over-year, supported by durable demand trends and lower competitive capacity on Frontier routes.”
“We are reaffirming our full year 2026 outlook for organic growth in a range of 7.5%-8%, including approximately 9.5% for the Big Three segments, and for our margins to rise by 100 basis points year-over-year to approximately 40%.”
“The gross margin impact is comprised of approximately $11 million due to the lost volume from the shutdown and approximately $6 million from elevated labor, freight, and expediting costs during the post-implementation ramp-up.”
“transplant ecosystem and at the macro level, we are reiterating our revenue guidance for the full year 2026 between $727 million-$757 million, representing a 20%-25% growth over full year 2025.”
“These ranges do not include any contribution from the pending Cornerstone acquisition, and we expect to provide an update to 2026 guidance after closing the transaction.”
“Jim, as we layer the Merck and Gilead wins on top of the $350 million of TCV that was already earmarked for revenue in 2026, how much visibility and confidence do you have in hitting the implied $410 million of data revenue guidance, and what are the potential levers for upside there?”
“Looking to the remainder of 2026, first quarter 2026 revenue plus firm backlog and options for the legacy Tidewater fleet represents $1.1 billion of revenue for the full year, representing approximately 84% of the midpoint of our legacy Tidewater 2026 revenue guidance.”
“Non-GAAP operating margin also improved significantly by more than 500 basis points year-over-year, driven by higher recurring revenue and a continued focus on operating leverage to deliver profitable growth.”
“Despite the workers' compensation headwind I mentioned earlier, PeopleReady segment profit margin was up 10 basis points, driven by targeted cost actions to deliver efficiencies and improve profitability.”
“While growth remains healthy, we have seen a modest slowdown over the past year, particularly in Southern Nevada, which we view as somewhat localized and timing-related rather than indicative of a change in long-term demand trends, which, as Karen noted, project population growth rates in both Arizona and Nevada to trend near 5% from 2026 to 2031, according to S&P.”
“We posted revenue of $944 million, roughly $20 million above the high end of our guidance range, delivered earnings per share of $1.15, $0.05 above the high end of our guidance range, and paid $107 million in quarterly dividends.”
“Lastly, we are pleased to confirm our 2026 guidance, which anticipates significant sales growth and even stronger growth in adjusted EBITDA within a challenging macro environment and where pool starts will be about flat from last year.”
“Despite typical first quarter headwinds, Qelbree's growth continues to be solid and is coming from both patient populations, with adult prescription growth of 27% and pediatric prescription growth of 15%.”
“We're increasing our guidance ranges for 2026 as follows: Revenue of $3.7 billion-$3.8 billion, which at the midpoint is a 20% increase over previous guidance and represents more than 50% growth over 2025.”
“Most recently, I served as CEO of Tactile Medical, where we grew revenue from $187 million to approximately $300 million.”
“Looking ahead, we expect our ongoing free cash flow, combined with proceeds from the sale of Çöpler before the end of the third quarter of 2026, will further strengthen the balance sheet and enhance our ability to continue to allocate capital with discipline while prioritizing high return growth opportunities and long-term value creation.”
“Gross margin for the quarter was 37.7% compared to 41.4% in the fourth quarter, and reflects the ongoing impact of supply chain dynamics, but especially revenue and product mix.”
“Calendar 2026 marks our third full year of operation in the market with our business on track for substantial growth.”
“Turning back to the full year, we continue to estimate a foreign exchange benefit of approximately 100 basis points on sales growth and are holding operating margin in the range of 21%-21.5%, an increase of 50 basis points-100 basis points over prior year, despite significant headwinds from tariffs annualizing and inflationary impacts.”
“The Q3 GAAP diluted earnings per share was $0.72 compared to guidance of at least $0.52, and non-GAAP diluted EPS was $0.84 versus guidance of at least $0.60 due to higher gross margins.”
“During the first quarter of 2026, we generated revenue and grant income of $3.1 million, driven primarily by the progress towards the site acceptance testing milestone under our Line Installation Agreement with SK On and performance on our assistance agreement with the U.S.”
“The expected sources of growth are consistent with the drivers that we saw in Q1, with the one key difference being that our Q2 revenue guidance assumes approximately a half point of FX tailwinds versus the more than 2 points of FX tailwinds that we saw in Q1.”
“While Andaz will certainly provide a lift to our results all year, the impact will become less pronounced as we get further into the year and begin to lap more of last year's operations, with the revenue growth benefit estimated at approximately 500 basis points in the second quarter and 150-200 basis points in each of the third and fourth quarters.”
“Our GAAP gross profit percentage was 29.2% and adjusted gross profit percentage was 29.6%, slightly below our expectations and impacted by product mix, higher freight costs, tariffs, and temporary labor inefficiencies as we start new lines and train new employees to meet the very strong demand we see ahead.”
“As a reminder, our full year 2026 guidance does not factor in any potential impact of M&A.”
“ACV growth was primarily driven by our top 20 pharma customers as these customers broaden their platform access, onboard new products, and integrate our platform more deeply into their R&D organizations.”
“We expect this to increase on a quarterly basis throughout 2026 due to investments in CMC supporting RM-718, increased spending on clinical trials, increased spending on clinical supply of bivamelagon ahead of our planned phase III trial in hypothalamic obesity, and the ongoing build-out of our team in Japan and preclinical work associated with our CHI program.”
“As it pertains to our updated pro forma guidance for 2026, which now excludes the immunodiagnostics business in China, we are now looking for organic growth of 3%-4%, adjusted operating margins of 28.4%, and adjusted earnings per share of $5.20-$5.30, which includes a 20% reduction related to the planned divestiture, offset by $0.05 of benefit from improved operational execution throughout the year.”
“Shifting to gross margin, we expect gross margin in the second quarter of 2026 of between 54.1% and 54.6%, which implies an increase of 25 basis points year-over-year at the midpoint of the range.”
“We expect 2026's free cash flow in the range of $125 million-$135 million for the full year, flat with prior year performance at the midpoint, and a free cash flow margin of approximately 15.5%.”
“Intelligent Devices margin of 20.9% increased by 320 basis points year-over-year and was ahead of our expectations due to positive price cost inclusive of productivity, higher sales volume, and favorable mix, partially offset by higher compensation.”
“As a result, we are maintaining our 2026 revenue guidance for total revenues of $275 million-$290 million, including net product sales of $255 million-$265 million.”
“Including these announcements, our firm full year 2026 and 2027 contract coverage is currently 86% and 73% respectively, providing a strong base for future cash flow and a line of sight to continued debt and interest expense reduction.”
“We are reiterating our expectation for 9%-13% organic growth while updating our reported revenue guidance to reflect the sale of our non-core and low-margin Polymem business.”
“We continue to expect to recognize GAAP revenue of $50 million-$65 million for the full year of 2026.”
“Secondly, in terms of profitability projections, given that PRVs are selling for, you know, substantially over $100 million at this point, any color on what you're modeling in terms of PRV monetization and whether we can expect that full year 2027 profitability to be sustainable?”
“For AMT-260 in refractory mesial temporal lobe epilepsy, enrollment in our phase I/II-A study is on track, and we expect to report data from the first cohort in the second quarter.”
“With this strong performance, EPS for the first quarter of 2026 was $1.95 per diluted share, and our free cash flow was $93.6 million, representing a 53% margin compared to 67% in the prior year.”
“We remain focused on improving cash flow generation still expect positive cash flow for the full-year, now expected to be in the range of $100 million-$120 million, with positive cash flow driven by higher revenue in the second half of the year.”
“Pulling all this together, for the second quarter, we expect low single-digit revenue growth on a currency-neutral basis, a low single-digit or approximately 3% decline in transaction margin dollars, transaction margin dollars excluding interest to decline low single digits or approximately 2%, mid-single-digit growth in non-transaction OpEx, and non-GAAP EPS to decline by high single digits or approximately 9%.”
“Restaurant-level adjusted EBITDA decreased $1.8 million-$34.8 million, with margins declining approximately 170 basis points to 19.1% in the quarter versus 20.8% in the prior year.”
“All these changes did not impact our guidance for the year, which remains in reiterating digital revenue growth of mid to high single digits, delivering total company adjusted EBITDA in the $310-$340 range.”
“We remain on pace to complete approximately 30 securitizations in 2026, which we expect will build a substantial foundation of investments with returns on equity in the low to mid-teens to support future earnings.”
“Net cash used in operating activities of $1 million was in line with the prior year, primarily due to improved earnings, which offset higher working capital driven by the increased demand.”
“Correspondent channel margins were 28 basis points, up from 25 basis points in the prior quarter due to a shift in mix towards higher margin government loans given the increased levels of competition from the GSE cash window, combined with a meaningful increase in average revenue per loan.”
“Albert, just going back to last December's guidance call, you highlighted $17 billion of annual revenue impacted by LOEs by 2030, and now with the tafamidis patent settlement extending that to mid-2031, your comments that you are aiming to achieve high single-digit, five-year revenue growth, starting in 2029.”
“The first quarter distribution margin increased by $0.07 per share compared to the year-ago period and largely reflects incremental gas margin from the third quarter 2025 GSMP II extension roll-in, an increase in the number of customers in the quarter, and higher gas demand outside of the decoupling mechanism.”
“That backlog provides us with good visibility into the revenue ramp ahead, and we are reiterating our full-year 2026 revenue guidance of $24 million-$27 million, which implies approximately 357%-415% growth compared to 2025.”
“Finally, we are maintaining our free cash flow margin guidance of 19%, which implies year-over-year free cash flow margin expansion of approximately 280 basis points.”
“These include all statements about our competitive position, product advantages and growth opportunities, anticipated industry trends, our business and strategic priorities, our OpEx targets, the impact of our recent acquisition, the development and expansion of our products, our products' capabilities and performance, and our revenue guidance for the second quarter of 2026 and long-term financial targets.”
“On slide 22, we are affirming our annual diluted earnings per share guidance range of $5.22-$5.62, which is expected to produce a return on equity of approximately 12%.”
“We expect to see year-on-year growth in off-lease volumes throughout the remainder of 2026 and beyond.”
“This surge in demand across both front-end and advanced packaging resulted in first quarter revenue above our original guidance range and is expected to continue with the heightened outlook for the second quarter revenue, which at the midpoint represents a 20% increase year-over-year.”
“Turning to segment performance, our Offshore Manufactured Products segment generated revenues of $91 million and Segment Adjusted EBITDA of $19 million in the first quarter, resulting in an Segment Adjusted EBITDA margin of 20%.”
“We continue to meet our growth targets while maintaining a strong focus on customer affordability, which was particularly important during a volatile winter.”
“Moving down the P&L, pro forma non-GAAP adjusted growth margin was 70.7%, a 40 basis point improvement over prior year, reflecting the impact of freight and logistics productivity improvements, partially offset by unfavorable geography mix.”
“During the quarter, 12 units were sold or placed under contract, compared to a full year underwriting assumption of six unit sales.”
“The optimal dose, which is the medium dose, demonstrated a 31% reduction in lesion growth relative to control at 12 months, with a P value of less than 0.05.”
“In fact, revenue from our high power business grew up to 25% year-over-year, with all four of our targeted high power end markets increasing sequentially in Q1.”
“The company reported that 2.5 million members globally, 103% year-over-year bookings growth in 2025, a $1.1 billion exit run rate, and positive operating cash flow in 2025.”
“The new project acquisitions that make that up as designed will ensure long-term, high margin, and recurring revenue streams, as reflected in the strong contract backlog growth that, as you see, is over $1.3 billion, made up primarily of our own and operate projects now, projects that are pre-funded through our existing Asset Vault platform.”
“We are targeting mid-single-digit organic growth in Sealing Technologies, while at AST, we are targeting at least high single-digit organic growth, with both segments capable of generating 30% adjusted segment EBITDA margins ±250 basis points through 2030.”
“We expect Affordable Care, a dental business specializing in higher margin tooth replacement and implant services, to come off non-accrual in the coming quarters as the lending group effectuates a change in control.”
“We expect to increase installed capacity by an additional 50% through the end of fiscal 2027, supported by a pipeline of safe harbored investment options in markets with supportive policy and strong demand growth.”
“As a result, we've adjusted our full year same store SHOP NOI growth to a range of 1%-3%.”
“With INGREZZA guidance reaffirmed at $2.7 billion-$2.8 billion, CRENESSITY now annualizing at over $600 million per year, and the pending addition of VYKAT XR to our commercial portfolio, we are well-positioned to deliver record net product sales in 2026.”
“Beyond Q1 revenue, we reported solid gross margin of 69% in line with our full year range.”
“Q2 total revenue guidance assumes a $10 million negative impact from Tinder's user experience tests and a $20 million negative impact from lower Azar direct revenue.”
“We've said that we target about 10%-20% of Bitcoin reserves annually in digital credit volume.”
“These results reflect ongoing focus on our four priority areas with highlights that include solid execution across our broad portfolio of production and development programs, backlog growth of 18% year-over-year and a sequential increase of 12-month backlog of 10.3%, a streamlined operating structure enabling increased positive operating leverage and significant margin expansion, and continued progress on Free Cash Flow drivers with Net Working Capital down 4.1% year-over-year.”
“For the Cash App impact, yeah, I mentioned that, you know, for the full year, we had stated 1.5-2 percentage points of gross profit growth impact.”
“A strong domestic and international demand drove increased Gulf Coast margins, resulting in an incremental $596 million of adjusted EBITDA.”
“We think the combination of revenue growth driving gross margin, the creative cog, the hosting cog, and the other cogs, having discipline around them will put us, you know, squarely in a position to stay in the long-term target of 75%-80%.”
“Like I said, it's part of the reason why, you know, our guidance is the back half of 2026 is, you know, one of these, you know, bad multifamily loans roll into the next quarter can be a, you know, $0.03 or $0.04 swing in DE or the timing of that resolution.”
“When I'm looking at pricing above 4%, are there any potential headwinds or impacts that we should be aware of or maybe that you have internally that could reduce the trajectory of this growth going forward?”
“While it takes time for the impact of these measures to fully flow through our financial results, we expect our SG&A to net sales ratio, excluding deal and restructuring costs, to improve in the second half of 2026 as these benefits phase in.”
“From a margin standpoint, we expect to drive significant improvement in gross margins approaching 30%, while operating expenses as a percentage of sales decrease to less than 20% from the 25% in 2025.”
“These two new offerings are another example of how we're innovating to help enterprise customers deliver on their AI ambitions, while simultaneously giving Lumen an opportunity to capture some of the over $2 billion in annual revenue currently served by carrier-neutral facility cross connects.”
“In April, we closed on sale-leaseback transactions that generated approximately $200 million of sale-leaseback proceeds and expect to complete approximately $400 million for the full year, supporting our ongoing focus on generating annual positive free cash flow.”
“Concrete revenues decreased by 1.9% year-over-year, despite a 14% increase in volumes.”
“I mean, does it mean you're targeting the mid to high single-digit organic growth for fiscal year 2027, and margins, I mean, coming down 50 basis points or 100 basis points?”
Try a ticker, period, category, or a call speaker.请尝试代码、期间、分类或电话会发言人。
This is a transcript-only, historically incomplete publication. Releases, filings, slides, consensus and price reaction are visibly marked as not joined; lower-evidence packets remain held instead of being inferred.这是仅基于电话会文本且历史覆盖尚不完整的发布。新闻稿、披露文件、演示材料、一致预期和股价反应均明确标注为未接入；证据不足的数据包会被暂缓，而非由推断补齐。